In the modern era, what is the role of beta-emitting bone-targeted radiopharmaceutical therapy?

Topics: Radiation Oncology • Palliation • Medical Oncology

Are you offering patients beta-emitters (Samarium-153 lexidronam, strontium-89) to any patients?

Answer from: Radiation Oncologist at Academic Institution

Since the approval of Radium-223 dichloride (Xofigo), I have been using it as the preferred radiopharmaceutical for patients with mCRPC. While use of Samarium-153 and Strontium-89 improves pain control, Radium-223 is an alpha-emitter and is the only FDA approved radiopharmaceutical that has been sho...

Comments

Radiation Oncologist at National Cancer Institute
In general agreement with Dr. @William W. Wong&nbs...

Radiation Oncologist at University of Missouri at Columbia, Ellis Fischel Cancer Cener
It is also to note that Samarium 153 EDTMP is (Qua...

Radiation Oncologist at Comprehensive Cancer Centers of Nevada
I try to use Samarium 153 often in breast and lung...

Related Questions